

Kyoto Drug Discovery & Development Co., Ltd.



<http://www.kyoto-drug.com>

Email ▶ info@kyoto-drug.com

Products

■ **KUS agents (Kyoto University Substances)** is a protein that consumes the intracellular ATP. It has a new pharmacological effect, which is inhibiting and preventing the degeneration and death of a cell by suppressing ATP consumption by VCP, an ATPase. In animal experiments, it was proven effective in inhibiting the progress of glaucoma, by having protective effects on retinal ganglion cells and optic nerve fibers. Glaucoma is the global no.1 cause of visual disability. Currently, the only treatments are surgery and drug therapy which reduces the intraocular pressure. KUS agent is expected to solve this unmet demand and become a new treatment drug with medical efficacy from its new mechanism. Furthermore, it can be expected to have applications in the cure of other retinal diseases, and degenerative diseases outside of the field of ophthalmology.

Message

As members of Kyoto Drug Discovery & Development CO, Ltd., our passion is to develop and provide the new cure for intractable diseases. As a pharmaceutical company who bears the work of research and development, we continually keep in mind our social responsibilities. We will continue our endeavor in research and development with the sincere gratitude towards the society, academia and the healthcare industry.

Reference information

Joint-Research's Participating Institute: National University Corporation, Kyoto University



京都市ライフイノベーション創出支援センター（公益財団法人京都高度技術研究所）

〒606-8507 京都市左京区聖護院河原町54 京都大学附属病院先端医療機器開発・臨床研究センター507号室
TEL:075-950-0880 FAX:075-950-0881

HP : <http://www.astem.or.jp/lifeinov/> E-mail : ikouyaku@astem.or.jp